HMGB1 Promotes the Proliferation and Metastasis of Lung Cancer by Activating the Wnt/β-Catenin Pathway

Overview

Journal Technol Cancer Res Treat

Specialties Biomedical Engineering
Oncology
Pharmacology

Date 2020 Aug 21

PMID 32815451

Citations 13

Authors

Xiao-Hui Wang

Shu-Ying Zhang

Mei Shi

Xiao-Peng Xu

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to investigate the role of high mobility group protein-1 (HMGB1) in the proliferation and migration of lung cancer cells. CCK-8 assays and colony formation assays were used to evaluate the effect of HMGB1 regulation on cancer cell viability and colony formation. Trans-well assays and wound healing assays were also performed. Our data showed that HMGB1 is upregulated in clinical lung cancer tissues compared with non-cancer tissues, and it is differentially expressed in lung cancer cell lines. The knockdown of HMGB1 in A549 lung cancer cells significantly reduced cell proliferation, viability and motility. In contrast, overexpression of HMGB1 in lung cancer H1299 cells significantly increased cell viability and motility. Western blotting showed that HMGB1 could promote epithelial-mesenchymal transition. The Wnt/β-catenin pathway was activated after overexpression of HMGB1 in H1299 cells, while it was inactivated by knocking down HMGB1 in A549 cells. These data suggest that HMGB1 promotes the proliferation and migration of lung cancer cells . The carcinogenic behavior of HMGB1 can be achieved by activating the Wnt/β-catenin pathway.

Citing Articles

Wnt/β-catenin signaling in the development and therapeutic resistance of non-small cell lung cancer.

Zhang Z, Westover D, Tang Z, Liu Y, Sun J, Sun Y J Transl Med. 2024; 22(1):565.

PMID: 38872189 PMC: 11170811. DOI: 10.1186/s12967-024-05380-8.

Tumor-associated neutrophils upregulate PANoptosis to foster an immunosuppressive microenvironment of non-small cell lung cancer.

Hu Q, Wang R, Zhang J, Xue Q, Ding B Cancer Immunol Immunother. 2023; 72(12):4293-4308.

PMID: 37907644 PMC: 10992448. DOI: 10.1007/s00262-023-03564-7.

Developmental expression of high-mobility group box 1 (HMGB1) in the mouse cochlea.

Liu W, Ming S, Zhao X, Zhu X, Gong Y Eur J Histochem. 2023; 67(3).

PMID: 37667832 PMC: 10518653. DOI: 10.4081/ejh.2023.3704.

Elevated HMGB1 promotes the malignant progression and contributes to cisplatin resistance of non-small cell lung cancer.

Ma Y, Feng Q, Han B, Yu R, Jin Z Hereditas. 2023; 160(1):33.

PMID: 37518006 PMC: 10388484. DOI: 10.1186/s41065-023-00294-9.

Function of as a competing endogenous RNA to promote progression in gastric cancer by regulating the axis.

Qin J, Zhen S, Wang J, Lv W, Zhao Y, Duan Y J Gastrointest Oncol. 2023; 14(3):1259-1278.

PMID: 37435216 PMC: 10331750. DOI: 10.21037/jgo-23-240.

References

Wang S, Du S, Lv Y, Zhang F, Wang W . MicroRNA-665 inhibits the oncogenicity of retinoblastoma by directly targeting high-mobility group box 1 and inactivating the Wnt/β-catenin pathway. Cancer Manag Res. 2019; 11:3111-3123. PMC: 6489654. DOI: 10.2147/CMAR.S200566. View

Luu T, Frankel P, Beumer J, Lim D, Cristea M, Appleman L . Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial. Cancer Chemother Pharmacol. 2019; 84(6):1201-1208. PMC: 6821594. DOI: 10.1007/s00280-019-03955-7. View

Liu X, Zhou M, Wu J, Wang J, Peng Q . HMGB1 release from trophoblasts contributes to inflammation during Brucella melitensis infection. Cell Microbiol. 2019; 21(10):e13080. DOI: 10.1111/cmi.13080. View

Amato J, Cerofolini L, Brancaccio D, Giuntini S, Iaccarino N, Zizza P . Insights into telomeric G-quadruplex DNA recognition by HMGB1 protein. Nucleic Acids Res. 2019; 47(18):9950-9966. PMC: 6765150. DOI: 10.1093/nar/gkz727. View

Janssen S, Mehta P, Bartscht T, Schmid S, Fahlbusch F, Rades D . Prevalence of metastases within the hypothalamic-pituitary area in patients with brain metastases. Radiat Oncol. 2019; 14(1):152. PMC: 6712746. DOI: 10.1186/s13014-019-1337-6. View

Lin X, Bloom M, Du Z, Hao Y . Trends in disability-adjusted life years of lung cancer among women from 2004 to 2030 in Guangzhou, China: A population-based study. Cancer Epidemiol. 2019; 63:101586. DOI: 10.1016/j.canep.2019.101586. View

Cohen J, Lin P, Sheinson D, Wong W, Wu N, Yim Y . Are National Comprehensive Cancer Network Evidence Block Affordability Ratings Representative of Real-World Costs? An Evaluation of Advanced Non-Small-Cell Lung Cancer. J Oncol Pract. 2019; 15(11):e948-e956. DOI: 10.1200/JOP.19.00241. View

Das S, Mishra K, Chanda S, Ganju L, Singh S . CXCR7: A key neuroprotective molecule against alarmin HMGB1 mediated CNS pathophysiology and subsequent memory impairment. Brain Behav Immun. 2019; 82:319-337. DOI: 10.1016/j.bbi.2019.09.003. View

Kim Y, Baek D, Lee S, Park D, Kang H, Cho B . Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer. Cancer Lett. 2019; 466:23-34. DOI: 10.1016/j.canlet.2019.09.005. View

10.

Tang L, Chai W, Ye F, Yu Y, Cao L, Yang M . HMGB1 promotes differentiation syndrome by inducing hyperinflammation via MEK/ERK signaling in acute promyelocytic leukemia cells. Oncotarget. 2017; 8(16):27314-27327. PMC: 5432337. DOI: 10.18632/oncotarget.15432. View

11.

Nakada T, Noda Y, Kato D, Shibasaki T, Mori S, Asano H . Risk factors and cancer recurrence associated with postoperative complications after thoracoscopic lobectomy for clinical stage I non-small cell lung cancer. Thorac Cancer. 2019; 10(10):1945-1952. PMC: 6775224. DOI: 10.1111/1759-7714.13173. View

12.

Wang Y, Jiang Z, Yan J, Ying S . HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma. Dis Markers. 2019; 2019:4183157. PMC: 6390248. DOI: 10.1155/2019/4183157. View

13.

Jurmeister P, Bockmayr M, Seegerer P, Bockmayr T, Treue D, Montavon G . Machine learning analysis of DNA methylation profiles distinguishes primary lung squamous cell carcinomas from head and neck metastases. Sci Transl Med. 2019; 11(509). DOI: 10.1126/scitranslmed.aaw8513. View

14.

Levy A, Hendriks L, Le Pechoux C, Falk S, Besse B, Novello S . Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey. Lung Cancer. 2019; 136:145-147. DOI: 10.1016/j.lungcan.2019.08.007. View

15.

Xie Z, Wang F, Xiao Z, Liu S, Lai Y, Tang S . Long noncoding RNA XIST enhances ethanol-induced hepatic stellate cells autophagy and activation via miR-29b/HMGB1 axis. IUBMB Life. 2019; 71(12):1962-1972. DOI: 10.1002/iub.2140. View

16.

Rizk N, Sallam A, El-Ansary A, El-Mesallamy H . HMGB1 and SEPP1 as predictors of hepatocellular carcinoma in patients with viral C hepatitis: Effect of DAAs. Clin Biochem. 2019; 70:8-13. DOI: 10.1016/j.clinbiochem.2019.05.017. View

17.

Zhong Y, Jiang L, Lin H, Li X, Long X, Zhou Y . Overexpression of KIF18A promotes cell proliferation, inhibits apoptosis, and independently predicts unfavorable prognosis in lung adenocarcinoma. IUBMB Life. 2019; 71(7):942-955. DOI: 10.1002/iub.2030. View